Investor-focused update underscores enrollment momentum, biomarker strategy, and near-term data readouts designed to de-risk development of (Z)-Endoxifen and other endocrine therapies for DCIS Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, today announced that Laura J. Esserman, MD, MBA, Professor of Surgery and Radiology at […]

(NASDAQ:SBET), Minneapolis, MN, Oct. 21, 2025 (GLOBE NEWSWIRE) — SharpLink Gaming, Inc. (Nasdaq: SBET) (“SharpLink” or the “Company”), one of the world's largest corporate holders of Ether (“ETH”) and prominent industry advocate of Ethereum adoption, today announced that as of October 19, 2025, SharpLink's total ETH holdings increased to 859,8531, reflecting the Company's continued commitment

DALLAS, Oct. 21, 2025 (GLOBE NEWSWIRE) — Solenic Medical, a medical device company developing an innovative treatment for orthopedic implant infections, today announced the successful, FDA-authorized compassionate use of its investigational Alternating Magnetic Field (AMF) technology. The noninvasive AMF treatment was delivered as an adjunct to surgery in a patient with a serious medical condition

Research Triangle Park, N.C., Oct. 21, 2025 (GLOBE NEWSWIRE) — First-in-human trial of investigational gene therapy AB-1002 designed to evaluate safety and preliminary efficacy in participants with New York Heart Association (NYHA) Class III heart failure No adverse events were deemed related to AB-1002, and clinically meaningful improvement of several efficacy assessments was seen in

(NasdaqGM:CSLR),(NasdaqGM:SPWR),(NASDAQ:SPWRW), OREM, Utah, Oct. 21, 2025 (GLOBE NEWSWIRE) — SunPower, the “Company,” or Nasdaq: “SPWR”, a solar technology, services, and installation company, will present its Q3'25 results via webcast today Tuesday, October 21 at 1:00pm ET. Interested parties may access the webcast by registering here or by visiting the Events page within the IR section

SAN FRANCISCO, Oct. 21, 2025 (GLOBE NEWSWIRE) — The NIH has awarded a new grant to Posit Science, the maker of the online BrainHQ brain exercises, to advance research, which showed in a neuro-imaging study published last week, that their brain exercises can significantly upregulate the production of a key brain chemical (acetylcholine) – known

(NASDAQ:PLTK), HERZLIYA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) — Playtika Holding Corp. (NASDAQ:PLTK) announced today that it will release financial results for the third quarter of 2025 before U.S. markets open on Thursday, November 6, 2025. On the same day, Playtika management will hold a conference call to discuss the results at 5:30 AM Pacific

SUNNYVALE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) — Real-Time Innovations (RTI), the software framework company for physical AI systems, today announced that RTI Connext(R) has been named a Gold Honoree in the 2025 Military + Aerospace Electronics Innovators Awards. This recognition highlights RTI's impact – from prime contractors to emerging innovators – in fielding new

NEW YORK, Oct. 21, 2025 (GLOBE NEWSWIRE) — Setting a new benchmark for luxury travel, Preferred Hotels & Resorts is proud to unveil its 2025 Live Like a Legend experience collection – an annual, exclusive offering of rare, one-of-a-kind moments from the most coveted luxury hotels around the globe. With six bespoke journeys, each thoughtfully

(NASDAQ:NERV), Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants. Minerva and the FDA have defined a path forward for roluperidone's clinical development and NDA resubmission. Further $40 million proceeds may be received in connection with cash exercise of Tranche B warrants